D5Ertd577e Activators
Pramel48, predicted to enable ubiquitin ligase-substrate adaptor activity and be part of the Cul2-RING ubiquitin ligase complex, plays a crucial role in cellular processes. As part of the predicted functions, Pramel48's activation involves intricate regulation, with a focus on ubiquitin-mediated degradation, epigenetic modulation, and pathway regulations. The Cul2-RING ubiquitin ligase complex, in which Pramel48 is predicted to participate, is a key regulator of protein ubiquitination and degradation. Chemicals like MLN4924 indirectly activate Pramel48 by inhibiting cullin neddylation, preventing the activation of the Cul2-RING complex and influencing Pramel48's ubiquitin ligase-substrate adaptor activity within the cytoplasm.
Epigenetic modulators, such as A-485, GSK-J4, and JQ1, indirectly activate Pramel48 by influencing histone acetylation or demethylation, highlighting the interconnected regulatory network between epigenetic modifications and Pramel48 expression. Pathway regulators like Rigosertib and ATR inhibitor (VE-821) indirectly activate Pramel48 by influencing the PI3K/Akt and DNA damage response pathways, respectively. Understanding the detailed mechanisms of Pramel48 activation sheds light on its role as a ubiquitin ligase-substrate adaptor and its involvement in cellular processes. The interconnected regulatory networks, including ubiquitin-mediated degradation, epigenetic modifications, and pathway regulations, showcase the sophisticated nature of Pramel48's regulation within cellular contexts. Further exploration into these mechanisms will contribute to a comprehensive understanding of Pramel48's role in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924, a NEDD8-activating enzyme (NAE) inhibitor, indirectly activates Pramel48 by inhibiting cullin neddylation. Inhibition of neddylation prevents the activation of the Cul2-RING ubiquitin ligase complex, influencing Pramel48's ubiquitin ligase-substrate adaptor activity within the cytoplasm. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $122.00 $219.00 | 2 | |
Nutlin-3, a small molecule inhibitor of MDM2, indirectly activates Pramel48 by stabilizing p53. Stabilized p53 enhances the expression of PRAME family members, including Pramel48, highlighting the interconnected regulatory network between p53 and Pramel48 in cellular processes. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, indirectly activates Pramel48 by inhibiting proteasomal degradation. Inhibition of proteasomal activity leads to the stabilization of Pramel48, emphasizing the importance of ubiquitin-mediated degradation in regulating Pramel48 expression and function. | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
MLN7243, an inhibitor of E3 ubiquitin ligase, indirectly activates Pramel48 by modulating the ubiquitin-proteasome system. Inhibition of E3 ubiquitin ligase influences the ubiquitin-mediated degradation of Pramel48, emphasizing the regulatory role of the ubiquitin-proteasome pathway in Pramel48 function. | ||||||
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
A-485, a histone deacetylase 7 (HDAC7) inhibitor, indirectly activates Pramel48 through epigenetic modulation. By inhibiting HDAC7, it promotes histone acetylation, leading to increased Pramel48 expression and subsequent cellular effects mediated by Pramel48 within various cellular contexts. | ||||||
NVP-AUY922 | 747412-49-3 | sc-364551 sc-364551A sc-364551B sc-364551C sc-364551D sc-364551E | 5 mg 25 mg 100 mg 250 mg 1 g 5 g | $150.00 $263.00 $726.00 $1400.00 $2900.00 $11000.00 | 3 | |
NVP-AUY922, a heat shock protein 90 (HSP90) inhibitor, indirectly activates Pramel48 by affecting protein folding and stability. Inhibition of HSP90 alters the stability and function of Pramel48, illustrating the role of protein folding machinery in regulating Pramel48 within cellular processes. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4, a Jumonji histone demethylase inhibitor, indirectly activates Pramel48 by influencing epigenetic regulation. Inhibition of Jumonji histone demethylases promotes the transcriptional activation of Pramel48, resulting in heightened expression and subsequent cellular effects mediated by Pramel48. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a BET bromodomain inhibitor, indirectly activates Pramel48 via epigenetic modulation. By inhibiting bromodomain-containing proteins, JQ1 promotes the transcriptional activation of Pramel48, leading to increased expression and cellular effects mediated by Pramel48 within various cellular contexts. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
VE-821, an inhibitor of the ATR kinase, indirectly activates Pramel48 by affecting the DNA damage response. Inhibition of ATR alters the expression and function of Pramel48, providing insight into the role of the ATR pathway in regulating Pramel48 within cellular processes. | ||||||